SCHEMBL3600124

SCHEMBL3600124

[NH]c1ccc2c(c1)NC(=O)C(N1CCC(O)CC1)C2

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.40
MEN1 O00255 2/20 0.40
APEX1 P27695 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
TRPV1 Q8NER1 5/20 0.39
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 2/20 0.35
MAPT P10636 2/20 0.35
GAA P10253 1/20 0.35
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
RAB9A P51151 1/20 0.33
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3602518 0.93 TRPV1 (0.36) KMT2AMEN1APEX1TDP1L3MBTL1
SCHEMBL3604332 0.90 DRD2 (0.42) KMT2AMEN1APEX1TDP1L3MBTL1
SCHEMBL3601332 0.85 TSHR (0.46) KMT2AMEN1DRD2DRD4TRPV1
SCHEMBL3600127 0.85 CA9 (0.41) KMT2AMEN1APEX1TDP1L3MBTL1
SCHEMBL3602345 0.84 DRD2 (0.41) KMT2AMEN1APEX1TDP1L3MBTL1
SCHEMBL3588943 0.84 DRD2 (0.44) KMT2AMEN1APEX1TDP1L3MBTL1
SCHEMBL3602308 0.84 DRD2 (0.41) KMT2AMEN1APEX1TDP1L3MBTL1
SCHEMBL3595501 0.84 DRD2 (0.38) KMT2AMEN1APEX1TDP1L3MBTL1
SCHEMBL3596748 0.84 TRPV1 (0.37) KMT2AMEN1APEX1TDP1L3MBTL1
SCHEMBL3588007 0.83 DRD2 (0.40) KMT2AMEN1APEX1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 KMT2A 906/4885MEN1 2424/4885APEX1 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.